(Q38358410)

2 September 2017

1 reference

title

Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). (English)

1 reference

non-small-cell lung carcinoma

2 September 2017

1 reference

based on heuristic

inferred from title

author name string

Nesaretnam Barr Kumarakulasinghe

series ordinal

1

1 reference

PubMed ID

25689095

2 September 2017

Nico van Zanwijk

series ordinal

2

1 reference

PubMed ID

25689095

2 September 2017

Ross A Soo

series ordinal

3

1 reference

2 September 2017

17 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

20

1 reference

2 September 2017

3

1 reference

2 September 2017

370-378

1 reference

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

2 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Comprehensive molecular profiling of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Targeting anaplastic lymphoma kinase in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

BRAF-mutations in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

MET signaling: novel targeted inhibition and its clinical development in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

KIF5B-RET fusions in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Immunotherapy in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12490

21 January 2018

Identifiers

DOI

10.1111/RESP.12490

1 reference

2 September 2017

1 reference

PubMed ID

25689095